High-affinity CD16-expressing natural killer cell therapy (NantKwest)

N/A

Report date: 2024/12/13 20:00:39

Base Information

Drug NameHigh-affinity CD16-expressing natural killer cell therapy (NantKwest)
Drug Alias NameCD-16 NK-92 cellsNK-92 [CD16.158V, ER IL-2]High affinity natural killer cells - NantKwestNK-92 [CD16.158V ER IL-2]
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionNatural killer cell replacementsImmunologic cytotoxicity
TargetsNot applicable
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungPancreatic Neoplasms +[15] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNantkwest Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesImmunitybio IncUniversity Of Minnesota
Active IndicationsN/A
Inactive IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungPancreatic Neoplasms +[15] 

Other Information

ATC CodeN/A
Related LinksN/A